BMS, bluebird get FDA priority review for ide-cel in multiple myeloma

This article was originally published here

The companies are seeking approval for the use of ide-cel in adult patients with the disease who have been subjected to least three prior therapies. The investigational cell

The post BMS, bluebird get FDA priority review for ide-cel in multiple myeloma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply